Bevacizumab: all 1,786 studies that test it
Page 12 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.
- SGT-53 in Children With Recurrent or Progressive CNS MalignanciesWithdrawnNCT03554707Early Phase 1
- Single or Combined Protocols for NV-AMDCompletedNCT03552770Phase 4
- A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerStatus unknownNCT03533127Phase 3
- Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerActive, not recruitingNCT03526432Phase 2
- A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRCCompletedNCT03511963Phase 3
- XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal CancerStatus unknownNCT03511183Phase 2
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male SubjectsCompletedNCT03483649Phase 1
- Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva CombinationStatus unknownNCT03462212Phase 1/2
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1
- Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedNCT03395899Phase 2
- A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer PatientsActive, not recruitingNCT03390686Phase 3
- Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular CarcinomaTerminatedNCT03382886Phase 1
- Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal CancerWithdrawnNCT03380689Phase 1
- BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
- Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein OcclusionStatus unknownNCT03353324Phase 2/3
- Two Chemotherapy Regimens Plus or Minus BevacizumabActive, not recruitingNCT03351296Phase 2
- Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable DiseaseStatus unknownNCT03240549Phase 2
- BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).CompletedNCT03227263Phase 3
- Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular EdemaCompletedNCT03211741Phase 4
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung CancerCompletedNCT03196986Phase 3
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
- PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal CancerTerminatedNCT03176264Phase 1
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
- Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung CancerCompletedNCT03169335Phase 3
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy NetworkCompletedNCT03164655Phase 2
- A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Active, not recruitingNCT03148418Phase 3
- Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaActive, not recruitingNCT03141684Phase 2
- Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovatorWithdrawnNCT03131700Phase 1
- A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)Status unknownNCT03126799Phase 2
- Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal AdhesionStatus unknownNCT03095001Phase 2
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2
- Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT03063762Phase 1
- Outpatient Performed Pterygium Surgery StudyWithdrawnNCT03037736Phase 4
- Study of Bevacizumab(BAT1706) and Comparators in Healthy SubjectsCompletedNCT03030430Phase 1
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyActive, not recruitingNCT02997228Phase 3
- Bevacizumabe or Triamcinolone for Persistent Diabetic Macular EdemaCompletedNCT02985619Phase 2/3
- Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerTerminatedNCT02982694Phase 2
- "Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" StudyStatus unknownNCT02960828Not applicable
- A+C in Metastatic Lung Adenocarcinoma CancerStatus unknownNCT02946359Phase 2
- Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung CancerStatus unknownNCT02942043Phase 2
- Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabCompletedNCT02934529Phase 3
- Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)Status unknownNCT02919371Phase 1/2
- Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled GlaucomaCompletedNCT02901236Phase 2/3
- Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional StatusCompletedNCT02898012Phase 2
- ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+BevacizumabCompletedNCT02891824Phase 3
- Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryActive, not recruitingNCT02884648Phase 2
- Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLCStatus unknownNCT02879097Phase 3
- Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1
- Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 MeningiomaCompletedNCT02847559Phase 2
- Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent GlioblastomaTerminatedNCT02841332Not applicable
- Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)Active, not recruitingNCT02840409Phase 2
- Study of Nintedanib Plus Bevacizumab in Advanced Solid TumorsCompletedNCT02835833Phase 1
- Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade GliomaTerminatedNCT02833701Phase 1
- Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasCompletedNCT02829931Phase 1
- Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal CancerCompletedNCT02821559Phase 2
- Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCCStatus unknownNCT02812641Phase 2
- Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent GlioblastomaCompletedNCT02768389Early Phase 1
- The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy SurgeryCompletedNCT02767219Phase 3
- Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR MutationsCompletedNCT02759614Phase 3
- PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)Status unknownNCT02747823Phase 1
- Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung CancerStatus unknownNCT02743923Phase 3
- A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid TumorsCompletedNCT02715531Phase 1
- PRP vs Bevacizumab for PDR TreatmentCompletedNCT02705274Phase 2/3
- Bevacizumab and Nimustine in Patients With Recurrent High Grade GliomaCompletedNCT02698280Phase 2
- Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis PatientsWithdrawnNCT02695641Early Phase 1
- Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation TrialStatus unknownNCT02672995Phase 1
- Capecitabine + Bevacizumab in Patients With Recurrent GlioblastomaCompletedNCT02669173Phase 1
- Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid TumorsCompletedNCT02665416Phase 1
- Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialStatus unknownNCT02655536Phase 2
- Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid TumorsTerminatedNCT02648711Phase 1
- The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular EdemaStatus unknownNCT02645734Phase 2/3
- A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal CancerCompletedNCT02641873Phase 1
- Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerStatus unknownNCT02633189Phase 3
- Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic CancerCompletedNCT02620800Phase 1
- Strategies for Management of Corneal NeovascularisationStatus unknownNCT02594423Phase 4
- Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal CancerStatus unknownNCT02591667Phase 2
- Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory PapillomatosisStatus unknownNCT02555800Phase 2
- Strategies for Management of Recurrent PterygiumStatus unknownNCT02530801Phase 4
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)CompletedNCT02511405Phase 3
- Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal CancerCompletedNCT02497157Phase 2
- Phase I - Pharmacokinetic Comparability Study in Healthy Male VolunteersCompletedNCT02469987Phase 1
- Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical CancerCompletedNCT02467907Phase 2
- Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular DegenerationWithdrawnNCT02450981Phase 1
- Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable MetastasisCompletedNCT02439385Phase 2
- Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or BevacizumabActive, not recruitingNCT02436993Phase 2
- Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian CancerCompletedNCT02399592Phase 2
- INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
- Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)CompletedNCT02363751Phase 2
- Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerCompletedNCT02354131Phase 1/2
- FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeCompletedNCT02350530Phase 2
- NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First RelapseWithdrawnNCT02348255Phase 2
- Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRCStatus unknownNCT02339116Phase 3